| Subcribe via RSS




Therapy Acceleration Program (TAP)

July 28th, 2008 Posted in Cancer Research Notes, Leukemia & Lymphoma Society

TAP on a Roll

LLS’s innovative new partnership program, the Therapy Acceleration Program (TAP), continues to grow and help create opportunities for new blood cancer treatments.
Founded in 2007, TAP supports private sector and academic-based projects with the goal of moving more blood cancer therapies into the development pipeline.
The program now has nine partnerships with a range of companies, universities and hospitals.
“We’re definitely progressing,” said Louis DeGennaro, Ph.D., LLS’s chief scientific officer. “These partnerships represent the beginning of a fruitful, long-term collaboration with some of the world’s leading innovators.”
TAP partnerships include: 

  • Anjin Group, a biotechnology company with offices in Maryland and Massachusetts. TAP is funding the company’s lead product, a novel therapy for acute myelogenous leukemia.
  • Cleveland Clinic. LLS and the world-renowned Cleveland Clinic are joining forces to provide potentially lifesaving clinical trials for blood cancer patients.
  • MannKind Corp., a biotechnology company in California. TAP is supporting the company in its efforts to develop drugs to treat T-cell-based leukemia and lymphoma.
  • Memgen LLC, a San Diego-based biotechnology company. TAP is supporting a clinical trial to test a novel therapy for a form of chronic lymphocytic leukemia.


Taken form The LLS newsline. For more info please visit. www.LLS.org


Tags: ,

Related Posts & Pages

This entry was posted on Monday, July 28th, 2008 at 12:32 pm and is filed under Cancer Research Notes, Leukemia & Lymphoma Society. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

Comments are closed.